Kirk Nelson

Statistics

Publications

Citations

1.6K

H-Index

Active since

2006

Affiliations

Mapp Biopharmaceutical (United States)(Current)

Arcturus Therapeutics (United States)

Molsoft (United States)

Doctors Company (United States)

Advanced Light Source

Kirk Nelson is an author at Mapp Biopharmaceutical (United States) specializing in pharmacology, antibiotic resistance, and antibacterial pharmacology.

ORCID

Publications per year

2006–2024

Publications

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

Olga Lomovskaya, Dongxu Sun, Debora Rubio-Aparicio et al. · Antimicrobial Agents and Chemotherapy · 2017 · 347 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases

Scott J. Hecker, K. Raja Reddy, Olga Lomovskaya et al. · Journal of Medicinal Chemistry · 2020 · 212 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity

Kirk Nelson, Peera Hemarajata, Dongxu Sun et al. · Antimicrobial Agents and Chemotherapy · 2017 · 176 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae

Dongxu Sun, Debora Rubio-Aparicio, Kirk Nelson et al. · Antimicrobial Agents and Chemotherapy · 2017 · 166 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents

Leslie W. Tari, Xiaoming Li, Michael Trzoss et al. · PLoS ONE · 2013 · 104 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

1–5 of 18